Gay, Nathan D <br/><br/>
Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours.  [electronic resource] 

 -  Current oncology (Toronto, Ont.)  12 2019 
 - e791-e792 p.  digital 
<br/><br/> Publication Type: Letter; Systematic Review 
<br/><br/><label>ISSN: </label>1718-7729 
<br/><br/><label>Standard No.: </label>10.3747/co.26.4845  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--therapeutic use<br/>Bevacizumab--therapeutic use<br/>Humans<br/>Neoplasms--drug therapy<br/>Randomized Controlled Trials as Topic